Psychedelic highlights | July 26 – 30

Psychedelic highlights | July 26 – 30 Here is a summary of the news from the…

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF)…

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

TORONTO, July 30, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496),…

Red Light Holland Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

Toronto, Ontario–(Newsfile Corp. – July 30, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX)…

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

VANCOUVER, BC, July 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company…

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

VANCOUVER, BC, July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the…

Tryp Therapeutics Announces Q3 2021 Financial Results

San Diego, California–(Newsfile Corp. – July 28, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the…

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today…

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI),…

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

Vancouver, British Columbia–(Newsfile Corp. – July 28, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF)…

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality

Innovative Ketamine clinical trial ranked in the 94th percentile by the CIHR peer review committee Suicidality…

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

NEW YORK, July 28, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing…